Determination 2 – Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Conditions: Multiple Myeloma
Interventions: Drug: Isatuximab; Drug: Iberdomide; Drug: Bortezomib (B); Drug: Dexamethasone; Drug: Melphalan; Drug: Linvoseltamab; Device: On Body Delivery System (OBDS)
Sponsors: Dana-Farber Cancer Institute; Sanofi; Bristol-Myers Squibb; Celgene Corporation; Regeneron Pharmaceuticals
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.